Bepridil Hydrochloride

CHEMBL1200382 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
403.0 g/mol
LogP
Phase
4

The hydrochloride salt of bepridil, a calcium channel blocker historically used for angina and heart rhythm disorders. It was withdrawn from widespread clinical use due to its risk of causing life-threatening ventricular arrhythmias, particularly in patients with underlying heart conditions. It remains a reference compound in cardiac research.

น้ำหนักโมเลกุล

403.0000 g/mol

TPSA

15.70 Ų

ด้านการรักษา

กลไกการออกฤทธิ์

Blocks L-type voltage-gated calcium channels in vascular smooth muscle and cardiac myocytes, reducing calcium influx during depolarization. This produces vasodilation, decreased myocardial contractility, and reduced heart rate.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Blocks L-type voltage-gated calcium channels in vascular smooth muscle and cardiac myocytes, reducing calcium influx during depolarization. This produces vasodilation, decreased myocardial contractility, and reduced heart rate.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1.Cl.O

InChI

InChI=1S/C24H34N2O.ClH.H2O/c1-21(2)19-27-20-24(25-15-9-10-16-25)18-26(23-13-7-4-8-14-23)17-22-11-5-3-6-12-22;;/h3-8,11-14,21,24H,9-10,15-20H2,1-2H3;1H;1H2

Molecular Formula

C24H35ClN2O

HBD / HBA

1 / 3

พันธะที่หมุนได้

10

อะตอมหนัก

28

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

The hydrochloride salt of bepridil, a calcium channel blocker historically used for angina and heart rhythm disorders. It was withdrawn from widespread clinical use due to its risk of causing life-threatening ventricular arrhythmias, particularly in patients with underlying heart conditions. It remains a reference compound in cardiac research.

Blocks L-type voltage-gated calcium channels in vascular smooth muscle and cardiac myocytes, reducing calcium influx during depolarization. This produces vasodilation, decreased myocardial contractility, and reduced heart rate.

Yes, Bepridil Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200382. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 50088. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.